본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Accegen

[Accegen] MDA-MB-468

Cat-No. ABC-TC0657

upload_image



미국 Accegen은 생명과학 연구와 의약품 개발을 지원하기 위해 다양한 세포주와 생물학적 제품을 제공하는 바이오 제품 제조 기업입니다.







제품 설명


MDA-MB-468




제품 번호


ABC-TC0657




제품 특징


Product Code

MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468; MD Anderson-Metastatic Breast-468

Species

Human

Cat.No

ABC-TC0657

Product CategoryTumor Cell Lines
Size/Quantity

1 vial

Cell Type

Epithelial

Shipping Info

Dry Ice

Growth Conditions

37 ℃

Source Organ

Breast

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Breast Cancer Cell Lines



Description


MDA-MB-468 is a human epithelial tumor cell line derived from pleural effusion of a 51-year-old Black female patient with metastatic adenocarcinoma of the breast, classified as triple-negative breast cancer (TNBC). The cell line exhibits characteristics of basal-like TNBC and has an epithelial-like morphology. The cells are small, adherent, and can present multinucleated characteristics as they approach confluence, with debris becoming noticeable. The karyotype is complex, with chromosomal aberrations commonly seen in TNBC. They highly express glucose-6-phosphate dehydrogenase (G6PD). The cell line is tumorigenic in immunodeficient mice, and while metastatic behavior is likely, it is not fully characterized. There are no specific viral properties associated with this cell line, and it serves as a model for studying triple-negative breast cancer.



Citation


When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).


Application


        • MDA-MB-468 is a key model for investigating the gene expression of basal-like TNBC and identifying the signal activators and transducers in signaling pathways that regulate or suppress cell growth and survival. Unlike ER-positive and HER2-amplified cancers, TNBC exhibits stronger resistance to hormone and HER2-targeted therapies, primarily due to the absence of frequent oncogenic driver mutations. Therefore, MDA-MB-468 is crucial in breast cancer research. For instance, the application of MDA-MB-468 in TNBC xenograft models has confirmed the inhibitory effect of IMMU-132, an antibody-drug conjugate targeting Trop-2, on tumor growth.



Recommended Medium And Supplement





Accegen의 모든 제품들을 만나 보세요!

 

PRODUCTS



Accegen - Official Distributor in South Korea "Morebio" 한국 공식 대리점 "모아바이오"